Trump to link Tylenol with autism as experts dispute claims

Group 1: Company Impact - Shares of Tylenol manufacturer Kenvue fell by 5.5% on the trading day following the announcement, marking a total decline of 17% in September due to the administration's potential link of the drug to autism [8] - Kenvue, which was spun off from Johnson & Johnson in 2023, stated that independent science shows no causal link between acetaminophen and autism, expressing concern over the health risks posed to expecting mothers by such claims [11] Group 2: Industry Context - The U.S. autism diagnosis rate has significantly increased, with the rate for 8-year-olds reaching 1 in 36 (2.77%) by 2020, up from 2.27% in 2018 and 0.66% in 2000, raising public concern [12] - Experts attribute the rise in autism diagnoses to improved screening methods and broader definitions of the condition, which have led to the identification of individuals with milder symptoms [14]